{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:36:34Z","timestamp":1780540594105,"version":"3.54.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Several maintenance therapies are available for treatment of patients with relapsed\/refractory (R\/R) diffuse large B cell lymphoma (DLBCL). The objective of this review was to assess the efficacy and safety of lenalidomide monotherapy in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MEDLINE, EMBASE, and the Cochrane Library databases were searched for publications up to April 7, 2021. Original studies that had information on lenalidomide monotherapy for DLBCL patients with R\/R status were included. Meta-analyses of response rates, adverse events (AEs), overall survival (OS), and progression-free survival (PFS) were performed. The pooled event rates were calculated using a double arcsine transformation to stabilize the variances of the original proportions. Subgroup analysis was used to compare patients with different germinal center B-cell-like (GCB) phenotypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 11 publications that examined DLBCL patients with R\/R status. These studies were published from 2008 to 2020. The cumulative objective response rate (ORR) for lenalidomide monotherapy was 0.33 (95% CI: 0.26, 0.40), and the ORR was better in patients with the non-GCB phenotype (0.50; 95% CI: 0.26, 0.74) than the GCB phenotype (0.06; 95% CI: 0.03, 0.11). The major serious treatment-related AEs were neutropenia, thrombocytopenia, respiratory disorders, anemia, and diarrhea. The median PFS ranged from 2.6 to 34 months and the median OS ranged from 7.8 to 37 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides evidence that lenalidomide monotherapy was active and tolerable in DLBCL patients with R\/R status. Patients in the non-GCB subgroup had better responsiveness.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.756728","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T09:47:13Z","timestamp":1638438433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Lenalidomide Monotherapy for Relapsed\/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"B1","volume-title":"World Cancer Report 2014","author":"Wild","year":"2014"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-Term Outcome of Patients in the LNH-98.5 Trial, the First Randomized Study Comparing Rituximab-CHOP to Standard CHOP Chemotherapy in DLBCL Patients: A Study by the Groupe d\u2019Etudes Des Lymphomes De l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive Conventional Chemotherapy Compared With High-Dose Chemotherapy With Autologous Haemopoietic Stem-Cell Transplantation for Relapsed Chemosensitive Hodgkin\u2019s Disease: A Randomised Trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"498342","DOI":"10.1155\/2012\/498342","article-title":"Lenalidomide in Diffuse Large B-Cell Lymphomas","volume":"2012","author":"Chiappella","year":"2012","journal-title":"Adv Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2016.1208170","article-title":"Lenalidomide for the Treatment of B-Cell Lymphoma","volume":"25","author":"Garciaz","year":"2016","journal-title":"Expert Opin Investigational Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1516","article-title":"A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type","volume":"138","author":"Beylot-Barry","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin\u2019s Lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Healthcare Interventions: Explanation and Elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Bmj"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.09.4110","article-title":"Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know","volume":"195","author":"Nishino","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"B12","volume-title":"Common Terminology Criteria for Adverse Events (Ctcae) Common Terminology Criteria for Adverse Events (Ctcae) V5. 0","year":"2017"},{"key":"B13","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26135","article-title":"Higher Response to Lenalidomide in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626","article-title":"An International Phase II Trial of Single-Agent Lenalidomide for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.151418","article-title":"Lenalidomide in Relapsed Refractory Non-Hodgkin\u2019s Lymphoma: An Indian Perspective","volume":"11","author":"Lakshmaiah","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.964702","article-title":"Lenalidomide Monotherapy in Heavily Pretreated Patients With Non-Hodgkin Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice","volume":"56","author":"Zinzani","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0103","article-title":"Lenalidomide in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Is It a Valid Treatment Option","volume":"101","author":"Mondello","year":"2016","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A Phase 2\/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator\u2019s Choice in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30016-9","article-title":"Lenalidomide Maintenance in Patients With Relapsed Diffuse Large B-Cell Lymphoma Who Are Not Eligible for Autologous Stem Cell Transplantation: An Open Label, Single-Arm, Multicentre Phase 2 Trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2742","article-title":"Long-Lasting Efficacy and Safety of Lenalidomide Maintenance in Patients With Relapsed Diffuse Large B-Cell Lymphoma Who Are Not Eligible for or Failed Autologous Transplantation","volume":"38","author":"Ferreri","year":"2020","journal-title":"Hematological Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0603","article-title":"Lenalidomide in Pretreated Patients With Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice","volume":"24","author":"Broccoli","year":"2019","journal-title":"oncologist"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) Monotherapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood.V126.23.1528.1528","article-title":"Phase IIa Study of Single-Agent MOR208 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"126","author":"Jurczak","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab Plus Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-MIND): A Multicentre, Prospective, Single-Arm, Phase 2 Study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1471","article-title":"RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) With a Real-World Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"27","author":"Zinzani","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.243567","article-title":"Application of Lenalidomide on Diffused Large B-Cell Lymphoma: Salvage, Maintenance, and Induction Treatment","volume":"131","author":"Ma","year":"2018","journal-title":"Chin Med J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914","article-title":"The Use of Molecular Profiling to Predict Survival After Chemotherapy for Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/35000501","article-title":"Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11864-017-0449-1","article-title":"Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy","volume":"18","author":"Karmali","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013046","article-title":"Prognostic Impact of Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP","volume":"97","author":"Cho","year":"2018","journal-title":"Medicine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide Downregulates the Cell Survival Factor, Interferon Regulatory Factor-4, Providing a Potential Mechanistic Link for Predicting Response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e64354","DOI":"10.1371\/journal.pone.0064354","article-title":"Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"8","author":"Yang","year":"2013","journal-title":"PloS One"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.756728\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T09:47:15Z","timestamp":1638438435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.756728\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":35,"alternative-id":["10.3389\/fonc.2021.756728"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.756728","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"article-number":"756728"}}